View in EDS

IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.

Saved in:
Bibliographic Details
Title: IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.
Authors: Martin-Broto J; Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain., Strauss SJ; Department of Medical Oncology, University College London Hospital, London, UK., Palmerini E; Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Ortopedico Rizzoli, Bologna, Italy.; Department of Medical Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA., Valverde C; Department of Medical Oncology, University Hospital Vall d'Hebron, Barcelona, Spain., Sebio A; Department of Medical Oncology, Sant Pau Hospital, Barcelona, Spain., Redondo A; Department of Medical Oncology, University Hospital La Paz, Madrid, Spain., Stacchiotti S; Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy., Grignani G; Medical Oncology Department, Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Italy., Aliberti S; Medical Oncology Department, Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Italy., Diaz-Beveridge R; Department of Medical Oncology, University Hospital La Fe, Valencia, Spain., Billalabeitia EG; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain., Cruz J; Department of Medical Oncology, Canarias University Hospital, La Laguna, Spain., Carrasco-Garcia I; Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain., Ibrahim T; Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Ortopedico Rizzoli, Bologna, Italy., Diaz-Martin J; Institute of Biomedicine of Seville, Spanish National Research Council-University of Seville, Department of Pathology, University Hospital Virgen del Rocio, Seville, Spain.; Biomedical Research Networking Center in Cancer (CIBERONC), Carlos III Health Institute, Madrid, Spain., Salguero-Aranda C; Institute of Biomedicine of Seville, Spanish National Research Council-University of Seville, Department of Pathology, University Hospital Virgen del Rocio, Seville, Spain.; Biomedical Research Networking Center in Cancer (CIBERONC), Carlos III Health Institute, Madrid, Spain., Gutierrez A; Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain., Mayordomo-Aranda E; Department of Pathology, University Hospital La Fe, Valencia, Spain., Ramos R; Department of Pathology, University Hospital Son Espases, Palma de Mallorca, Spain., Merino J; Department of Pathology, Fundación Jiménez Díaz University Hospital, Madrid, Spain., Collini P; Advanced Diagnostic Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy., Tirabosco R; Department of Pathology, University College London Hospital, London, UK., Bague S; Department of Pathology, Sant Pau Hospital, Barcelona, Spain., Romagosa C; Department of Pathology, University Hospital Vall d'Hebron, Barcelona, Spain., Carrera MA; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain., Ledesma P; Sofpromed Investigación Clínica, Palma de Mallorca, Spain., Hindi N; Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain., Moura DS; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain.
Source: Cancer communications (London, England) [Cancer Commun (Lond)] 2026 Mar 12; Vol. 46, pp. 0015. Date of Electronic Publication: 2026 Mar 12 (Print Publication: 2026).
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101723675 Publication Model: eCollection Cited Medium: Internet ISSN: 2523-3548 (Electronic) Linking ISSN: 25233548 NLM ISO Abbreviation: Cancer Commun (Lond) Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41836677
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Martin-Broto+J%22">Martin-Broto J</searchLink>; Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Strauss+SJ%22">Strauss SJ</searchLink>; Department of Medical Oncology, University College London Hospital, London, UK.<br /><searchLink fieldCode="AU" term="%22Palmerini+E%22">Palmerini E</searchLink>; Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Ortopedico Rizzoli, Bologna, Italy.; Department of Medical Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA.<br /><searchLink fieldCode="AU" term="%22Valverde+C%22">Valverde C</searchLink>; Department of Medical Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Sebio+A%22">Sebio A</searchLink>; Department of Medical Oncology, Sant Pau Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Redondo+A%22">Redondo A</searchLink>; Department of Medical Oncology, University Hospital La Paz, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Stacchiotti+S%22">Stacchiotti S</searchLink>; Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Grignani+G%22">Grignani G</searchLink>; Medical Oncology Department, Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Italy.<br /><searchLink fieldCode="AU" term="%22Aliberti+S%22">Aliberti S</searchLink>; Medical Oncology Department, Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Italy.<br /><searchLink fieldCode="AU" term="%22Diaz-Beveridge+R%22">Diaz-Beveridge R</searchLink>; Department of Medical Oncology, University Hospital La Fe, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Billalabeitia+EG%22">Billalabeitia EG</searchLink>; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Cruz+J%22">Cruz J</searchLink>; Department of Medical Oncology, Canarias University Hospital, La Laguna, Spain.<br /><searchLink fieldCode="AU" term="%22Carrasco-Garcia+I%22">Carrasco-Garcia I</searchLink>; Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain.<br /><searchLink fieldCode="AU" term="%22Ibrahim+T%22">Ibrahim T</searchLink>; Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Ortopedico Rizzoli, Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Diaz-Martin+J%22">Diaz-Martin J</searchLink>; Institute of Biomedicine of Seville, Spanish National Research Council-University of Seville, Department of Pathology, University Hospital Virgen del Rocio, Seville, Spain.; Biomedical Research Networking Center in Cancer (CIBERONC), Carlos III Health Institute, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Salguero-Aranda+C%22">Salguero-Aranda C</searchLink>; Institute of Biomedicine of Seville, Spanish National Research Council-University of Seville, Department of Pathology, University Hospital Virgen del Rocio, Seville, Spain.; Biomedical Research Networking Center in Cancer (CIBERONC), Carlos III Health Institute, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Gutierrez+A%22">Gutierrez A</searchLink>; Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain.<br /><searchLink fieldCode="AU" term="%22Mayordomo-Aranda+E%22">Mayordomo-Aranda E</searchLink>; Department of Pathology, University Hospital La Fe, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Ramos+R%22">Ramos R</searchLink>; Department of Pathology, University Hospital Son Espases, Palma de Mallorca, Spain.<br /><searchLink fieldCode="AU" term="%22Merino+J%22">Merino J</searchLink>; Department of Pathology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Collini+P%22">Collini P</searchLink>; Advanced Diagnostic Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Tirabosco+R%22">Tirabosco R</searchLink>; Department of Pathology, University College London Hospital, London, UK.<br /><searchLink fieldCode="AU" term="%22Bague+S%22">Bague S</searchLink>; Department of Pathology, Sant Pau Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Romagosa+C%22">Romagosa C</searchLink>; Department of Pathology, University Hospital Vall d'Hebron, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Carrera+MA%22">Carrera MA</searchLink>; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Ledesma+P%22">Ledesma P</searchLink>; Sofpromed Investigación Clínica, Palma de Mallorca, Spain.<br /><searchLink fieldCode="AU" term="%22Hindi+N%22">Hindi N</searchLink>; Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Moura+DS%22">Moura DS</searchLink>; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101723675%22">Cancer communications (London, England)</searchLink> [Cancer Commun (Lond)] 2026 Mar 12; Vol. 46, pp. 0015. <i>Date of Electronic Publication: </i>2026 Mar 12 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101723675 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2523-3548 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225233548%22">25233548 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Commun (Lond) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41836677
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.34133/cancomm.0015
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 0015
    Titles:
      – TitleFull: IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Martin-Broto J
      – PersonEntity:
          Name:
            NameFull: Strauss SJ
      – PersonEntity:
          Name:
            NameFull: Palmerini E
      – PersonEntity:
          Name:
            NameFull: Valverde C
      – PersonEntity:
          Name:
            NameFull: Sebio A
      – PersonEntity:
          Name:
            NameFull: Redondo A
      – PersonEntity:
          Name:
            NameFull: Stacchiotti S
      – PersonEntity:
          Name:
            NameFull: Grignani G
      – PersonEntity:
          Name:
            NameFull: Aliberti S
      – PersonEntity:
          Name:
            NameFull: Diaz-Beveridge R
      – PersonEntity:
          Name:
            NameFull: Billalabeitia EG
      – PersonEntity:
          Name:
            NameFull: Cruz J
      – PersonEntity:
          Name:
            NameFull: Carrasco-Garcia I
      – PersonEntity:
          Name:
            NameFull: Ibrahim T
      – PersonEntity:
          Name:
            NameFull: Diaz-Martin J
      – PersonEntity:
          Name:
            NameFull: Salguero-Aranda C
      – PersonEntity:
          Name:
            NameFull: Gutierrez A
      – PersonEntity:
          Name:
            NameFull: Mayordomo-Aranda E
      – PersonEntity:
          Name:
            NameFull: Ramos R
      – PersonEntity:
          Name:
            NameFull: Merino J
      – PersonEntity:
          Name:
            NameFull: Collini P
      – PersonEntity:
          Name:
            NameFull: Tirabosco R
      – PersonEntity:
          Name:
            NameFull: Bague S
      – PersonEntity:
          Name:
            NameFull: Romagosa C
      – PersonEntity:
          Name:
            NameFull: Carrera MA
      – PersonEntity:
          Name:
            NameFull: Ledesma P
      – PersonEntity:
          Name:
            NameFull: Hindi N
      – PersonEntity:
          Name:
            NameFull: Moura DS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 03
              Text: 2026 Mar 12
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2523-3548
          Numbering:
            – Type: volume
              Value: 46
          Titles:
            – TitleFull: Cancer communications (London, England)
              Type: main
ResultId 1